Incyte Corporation
INCY Healthcare Biotechnology NASDAQ
$103.27
+$1.28 (+1.26%)
Open: $101.57 | High: $103.42 | Low: $101.10 | Prev Close: $101.99
Market Cap: $20.27B
Volume: 587K | Avg: 2.3M
Last updated: January 26, 2026 at 06:03 PMInvestment Rating
Buy
Overall Score: 80/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 555
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 17.50 |
| P/B Ratio | 4.35 |
| P/S Ratio | 4.21 |
| EPS | $5.90 |
| Beta | 0.82 |
| Shares Outstanding | 196.32M |
| 52-Week High | $112.29 |
| 52-Week Low | $53.56 |
| SMA 50 | $102.30 |
| SMA 200 | $82.24 |
| Next Earnings | February 18, 2026 12:00 PM ET |
Financial Ratios
| Gross Margin | 91.9% |
| Operating Margin | 26.4% |
| Net Margin | 24.7% |
| ROE | 29.8% |
| ROA | 18.8% |
| Debt/Equity | 0.01 |
| Current Ratio | 3.19 |
| Quick Ratio | 2.86 |
Balance Sheet
| Total Assets | $5.44B |
| Total Liabilities | $2.00B |
| Total Equity | $3.45B |
|
|
|
| Cash | $1.69B |
| Total Debt | $43.54M |
| Net Debt | $-1,644,285,000 |
Income Statement
| Revenue | $4.24B |
| Gross Profit | $3.86B |
| Operating Income | $80.14M |
| Net Income | $32.62M |
|
|
|
| EBITDA | $408.16M |
| Revenue/Share | $24.60 |
Cash Flow
| Operating CF | $335.34M |
| CapEx | $86.26M |
| Free Cash Flow | $249.07M |
|
|
|
| Book Value/Share | $23.77 |
| Tangible Book/Share | $22.37 |
| Equity/Share | $23.77 |
Technical Indicators
| RSI (14) | 50.00 Neutral |
| MACD |
0.00
Signal: 0.00
|
| Volatility | 0.00% |
| Trading Signal | Neutral |
Performance & Returns
Insufficient historical data
Insufficient historical data (need 200+ days, have 0)Sector Comparison (Healthcare)
| Metric | INCY | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 17.5 | 35.7 | 30% |
| P/B Ratio | 4.35 | 0.18 | 50% |
| ROE (%) | 29.83% | 13.83% | 74% |
| Net Margin (%) | 24.69% | 9.32% | 80% |
| Stock Score | 555 | 466.0 | 83% |
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INCY | $103.27 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | 50.00 | 0.00 | 0.00% | 0 | Neutral | Mixed |
Candlestick Patterns
There wasn't any recognizable pattern for the INCY stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| INCY | Here's Why Incyte (INCY) is a Strong Momentum Stock | Neutral | zacks.com | Read More |
| INCY | Incyte Corporation $INCY Shares Purchased by Wealth Enhancement Advisory Services LLC | Neutral | defenseworld.net | Read More |
| INCY | Why Incyte (INCY) is a Top Value Stock for the Long-Term | Neutral | zacks.com | Read More |
| INCY | What Investors Should Know Before Buying Incyte | Neutral | seekingalpha.com | Read More |
| INCY | Donoghue Forlines LLC Invests $2.14 Million in Incyte Corporation $INCY | Neutral | defenseworld.net | Read More |
Recent Insider Trading
| Date | Insider | Position | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-01-20 | Morrissey Michael James | officer: EVP, Head of Tech. Operations | SELL | 429 | $102.62 | $44024 |
| 2026-01-16 | CAGNONI PABLO J | officer: President, R&D | BUY | 28475 | $106.21 | $3024330 |
| 2026-01-16 | Stein Steven H | officer: EVP & Chief Medical Officer | BUY | 19932 | $106.21 | $2116978 |
| 2026-01-16 | Issa Mohamed Khairie | officer: EVP, Head of US Oncology | BUY | 14237 | $106.21 | $1512112 |
| 2026-01-16 | Trotta Matteo | officer: EVP, GM, Dermatology US | BUY | 8542 | $106.21 | $907246 |
| 2026-01-16 | Tray Thomas | officer: Principal Accounting Officer | BUY | 2425 | $106.21 | $257559 |
| 2026-01-16 | Mayes Patrick A | officer: EVP & Chief Scientific Officer | BUY | 4218 | $106.21 | $447994 |
| 2026-01-07 | Issa Mohamed Khairie | officer: EVP, Head of US Oncology | SELL | 10856 | $109.07 | $1184064 |
| 2026-01-06 | Issa Mohamed Khairie | officer: EVP, Head of US Oncology | SELL | 8264 | $106.66 | $881438 |
| 2026-01-05 | Stein Steven H | officer: EVP & Chief Medical Officer | SELL | 15634 | $101.70 | $1589978 |
Company Information
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
| CEO | William Meury |
| Employees | 2617 |
| Country | US |
| IPO Date | 1993-11-04 |
| Exchange | NASDAQ |
| Website | https://www.incyte.com |
| Sector | Healthcare |
| Industry | Biotechnology |
Similar Stocks (Healthcare - Biotechnology)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category